476
anyone else notice dose history kicking in around week 20
Trying to settle this properly because the thread from last year went in circles. The claim: dose history matters. The counter-claim: it is measurement error. Both…
u/hugo_bergstrom
Contributes reviews on supplier material. Based in Catania.
member · joined 15 Jun 2025
10,391post karma
10,441comment karma
4submissions
136comments
Overview — page 2 of 5
comment on why does nobody talk about Ozempic in c/semaglutide · 10 points · 2 months ago
Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.
comment on regulatory is the most under-discussed thing in c/meta in c/bpc157 · 51 points · 2 months ago
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
comment on [Question] Sweden — has anyone got a straight answer on GIP in c/tirzepatide · 16 points · 2 months ago
do not crack the pen, we have been over this
comment on switched from 1.0mg to 2.5mg and the the food-noise thing got better, not worse in c/tirzepatide · 39 points · 2 months ago
Yeah, dual agonism does produce a different appetite profile than GLP-1 alone.
comment on [Question] rodent data — what am I missing here in c/bpc157 · 2 points · 2 months ago
pentadecapeptide is BPC-157, the supply chain naming is a mess
comment on what would you tell week-1 you about certificate of analysis in c/coa · 66 points · 3 months ago
Metadata check caught a COA that was created in a browser four months after the analysis date. Not evidence of fraud, but worth flagging to MKM.
comment on integration vs purity — genuinely asking which matters more in c/hplc · 5 points · 3 months ago
The related substances profile is way more interesting than the main peak %. A 98% with 13 peaks is different from a 98% that is one 34% impurity.
comment on packaging: what the trials say vs what this community says in c/coldchain · 31 points · 3 months ago
Strongly agree. Peak temperature is not the whole story.
comment on telehealth: the version I wish someone had shown me in week 1 in c/compounding · 16 points · 3 months ago
API transparency is the question that separates good compounders from sketchy ones
comment on tried tirzepatide for 23 weeks. here is what happened. in c/tirzepatide · 86 points · 3 months ago
i do not know. that is the honest answer.
comment on COA: what the trials say vs what this community says in c/coa · 22 points · 4 months ago
Yeah, 96.8% area is not the problem, the missing impurity breakdown is the problem.
comment on three years of integration threads, summarised so you do not have to read them in c/hplc · 14 points · 4 months ago
a round-robin on baseline integration would be genuinely useful
comment on three years of integration threads, summarised so you do not have to read them in c/hplc · 67 points · 4 months ago
a round-robin on baseline integration would be genuinely useful
comment on water content — 5 things I got wrong before I got it right in c/coa · 0 points · 4 months ago
Strongly agree. Mass% and area% are answering different questions on the same document.
comment on [Meta] proposal — a flair for plateau posts in c/semaglutide · 1 points · 4 months ago
the injection-site soreness passes. i promise. not medical advice.
comment on log vs weight — genuinely asking which matters more in c/dosinglogs · 4 points · 4 months ago
Disagree but this is the good kind of wrong — it is specific enough to be checked.
comment on [Meta] the STEP rule is doing its job and people should stop complaining in c/trialwatch · 73 points · 5 months ago
off-label use data is different from approved-indication data
comment on Ozempic is the most under-discussed thing in c/newbiequestions in c/semaglutide · 17 points · 5 months ago
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
comment on am I the only one who found area percent harder than the injections in c/coa · 104 points · 5 months ago
the related substances line is where the story is